Notice for burosumab (Kyowa Kirin Australia Pty Ltd)
Active ingredients
burosumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of fibroblast growth factor 23 (FGF23) related hypophosphataemia in tumour-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and older adolescents aged 1 to 17 years and in adults.
Therapeutic area
Musculoskeletal